Andreessen: “Doctor ChatGPT” Beats 99% of Doctors, Evidence Disagrees

Marc Andreessen is back in the headlines with a health-AI soundbite that traders are already pricing in. The billionaire investor says “Doctor ChatGPT” is already a better doctor than 99% of human ones. The claim, made on a recent podcast run, is stirring another round of debate over how quickly large language models can replace clinical work.

What Andreessen actually said

“Doctor ChatGPT is a better doctor than 99% of doctors. Doctors hate it when you say it, but it just is,” Andreessen said in a recent interview. Andreessen made the remark on Joe Rogan’s podcast in early June.

His pitch: “Patients should really want this, if only so that their doctors can have all the information at their fingertips. No human doctor can read all the medical literature and keep up with it every year. Another issue is drug interactions. When people get older, they don’t tend to get sick with just one thing.”

The evidence pushes back

A peer-reviewed JMIR study found physicians flagged 15% of the chatbot’s medical answers as potentially harmful. That is a wide margin for anything marketed as a physician replacement.

A newer study is more alarming. In February 2026, a Nature Medicine paper led by Mount Sinai urologist Dr Ashwin Ramaswamy tested OpenAI’s ChatGPT Health on 60 clinical scenarios. The tool failed to send 51.6% of true emergencies to the emergency room. It suggested a routine appointment instead. One missed case involved a patient going into respiratory failure.

Do you want to see how to make more plays? Do you want to find gains yourself?

Unusual Whales helps you find market opportunities through our market tide, historical options flow, GEX, and much, much more.

Create a free account here to start conquering the market with Unusual Whales.

Andreessen’s book is not neutral

Andreessen also has a stake in the answer. His firm has poured money into health-AI startups, including Hippocratic AI, Ambience Healthcare and Abridge. The louder the AI-doctor narrative gets, the better the mark-to-market on that portfolio.

Andreessen’s ‘99%’ framing collided in May 2026 with a personal embarrassment that suggested he does not understand the technology he is promoting. He posted a nearly 300-word ‘custom super prompt’ on X instructing ChatGPT to ‘never hallucinate or make anything up’ and to ‘double check all facts, figures, citations, names, dates, and examples’. Engineers and academics quickly pointed out that the instruction cannot be followed. Hallucinations are an architectural feature of large language models, not a behaviour that can be switched off by a system prompt.

Why it matters for markets

The comment lands as health-AI remains one of the hottest capital destinations in tech. Whether or not the “99%” number holds up, the meme itself moves flows into diagnostics, clinical documentation, and LLM infrastructure names.

OpenAI is currently facing a lawsuit from the family of 23-year-old Zane Shamblin, who allege the chatbot encouraged him to take his own life. Legal and regulatory overhang is now part of the health-AI trade, not just a headline risk. For more, see other news.

Options market and stocks to watch

Watch for reactions across the AI-and-healthcare stack:

MSFT: OpenAI’s largest backer and the closest public proxy for “Doctor ChatGPT” narratives. Watch for flow around any consumer-health rollout.

NVDA: Every clinical LLM deployment feeds compute demand. Watch for continued interest tied to healthcare AI capex.

GOOGL: Med-PaLM and Google Health are direct competitors in the medical LLM space. Watch for positioning if the debate expands.

UNH: Managed care names are the most exposed if AI triage tools shift utilization. Watch for headline sensitivity.

TEM: Tempus AI is a pure-play on clinical AI diagnostics. Watch for sympathy moves on any health-AI headline cycle.

Want more market intelligence? Create your free Unusual Whales account for options flow, market tide, GEX, and the full toolkit.